Business context and reporting period
Important entity distinction: This is Helix Acquisition Corp.’s Form 10-K, not an operating-company 10-K filed by MoonLake Immunotherapeutics. It covers the fiscal year ended December 31, 2021 and was signed February 17, 2022. Helix was a Cayman Islands SPAC with no operating business or revenue; it had agreed to combine with MoonLake Immunotherapeutics AG, a Swiss biotechnology company.
The proposed transaction would give Helix a controlling interest in MoonLake, with MoonLake as the operating company after closing. Helix expected the transaction to close in the first half of 2022, subject to shareholder and regulatory approvals and other conditions. The filing does not report MoonLake’s operating results.
Key financial metrics
| Metric | FY 2021 / December 31, 2021 | Prior period / December 31, 2020 |
|---|---|---|
| Revenue | None | None; inception-to-year-end period |
| General and administrative expenses | $4.57 million | $105,755; inception-to-year-end period |
| Net loss | $4.54 million | $90,838; inception-to-year-end period |
| Interest income on Trust Account | $27,691 | $14,917 |
| Cash used in operating activities | $611,071 | $316,692; inception-to-year-end period |
| Cash outside Trust Account | $666,790 | $1.34 million |
| Trust Account investments and cash | $115.04 million | $115.01 million |
| Total assets | $115.84 million | $116.63 million |
| Total liabilities | $7.90 million | $4.15 million |
Helix reported a working capital deficit of approximately $3.1 million. Current liabilities included $3.87 million of accrued expenses; the remaining $4.03 million of reported liabilities was deferred underwriting fees payable upon a completed business combination. Helix reported no outstanding working-capital loans and no long-term debt. Margins are not meaningful because Helix had no revenue or operating business.
Material changes versus the prior period
- General and administrative expenses rose substantially as Helix pursued the MoonLake transaction; the prior comparison covers only August 13 through December 31, 2020, not a full fiscal year.
- Net loss increased to $4.54 million from $90,838 in the shorter 2020 inception period. Cash outside the Trust Account declined by approximately $669,000 during 2021.
- Helix classified all 11.5 million public shares as temporary equity because redemption rights were outside its control. It identified a material weakness related to accounting for complex financial instruments and restated previously issued financial statements, including 2020 and 2021 interim periods.
Outlook, risks and unusual items
- The MoonLake transaction included a $115 million PIPE at $10 per share and a minimum $150 million cash-at-closing condition after redemptions, transaction expenses and PIPE proceeds. The filing states that the condition could prevent closing if redemptions were too high unless MoonLake waived it.
- Assuming no public-share redemptions, Helix estimated post-transaction fully diluted ownership of approximately 18.5% for public shareholders, 5.3% for the sponsor and initial shareholders, 18.5% for PIPE investors, and 57.8% for MoonLake parties. With maximum redemptions consistent with the stated net tangible asset requirement, estimated ownership would be approximately 0%, 6.5%, 22.6%, and 70.9%, respectively.
- Helix had until October 22, 2022 to complete a business combination or liquidate. Management and the auditor stated that the deadline and liquidity circumstances raised substantial doubt about Helix’s ability to continue as a going concern if no transaction closed. The financial statements were not adjusted for a potential liquidation.
- Management concluded that disclosure controls and internal control over financial reporting were ineffective at year-end because of the material weakness. Remediation steps had begun, but Helix gave no assurance they would fully resolve it. The auditor issued an unqualified opinion on the financial statements but did not opine on internal controls.
- Contingent and deferred transaction fees payable upon completion were estimated at approximately $9.1 million, including expense reimbursements. Other disclosed risks included redemption-related funding uncertainty, dilution, conflicts of interest, third-party claims against the Trust Account, and the possibility that public shareholders could receive less than $10 per share upon liquidation.
Most important facts for investors to verify
- Whether the MoonLake business combination closed, and the final cash available after redemptions, PIPE funding, expenses and any waiver of the minimum-cash condition.
- The final transaction terms, fully diluted share count, ownership allocation and actual dilution, compared with the filing’s illustrative assumptions.
- Helix’s restated financial statements and subsequent disclosures on remediation of the material weakness and effectiveness of financial reporting controls.
- The amount and payment of deferred underwriting and placement-agent fees, accrued expenses, and any other transaction-related obligations.
- MoonLake’s operating performance, cash runway, financing needs and business risks; these are not provided as operating results in this Helix filing.